-
2 months ago | 
academic.oup.com | Carolyn S P |van Veldhuisen
An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposity—the waist-to-height ratio (WHtR)—focuses on body fat content and distribution; is not distorted by bone or muscle mass, sex, or ethnicity; and may be particularly relevant in HFpEF.
-
Jan 7, 2025 | 
eprints.gla.ac.uk | Carolyn S P |van Veldhuisen
Solano, S. et al. (2025) Clinical characteristics and outcomes of patients with heart failure with preserved ejection fraction and with reduced ejection fraction according to the prognostic nutritional index: findings from PARADIGM‐HF and PARAGON‐HF. Journal of the American Heart Association, 14(1), e037782. (doi: 10.1161/JAHA.124.037782) (PMID:39719408) Text343856.pdf - Published Version Available under License Creative Commons Attribution Non-commercial.
-
Nov 20, 2024 | 
eprints.gla.ac.uk | John G.F |Carolyn S.P |van Veldhuisen
Monzo, L. et al. (2024) Machine learning approach to identify phenotypes in patients with ischemic heart failure with reduced ejection fraction.
-
Aug 31, 2024 | 
eprints.gla.ac.uk | De Boer |Carolyn S.P |van Veldhuisen |John J.V
Matsumoto, S. et al. (2024) Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.3383) (PMID:39215677) (Early Online Publication)Full text not currently available from Enlighten.
-
Jun 26, 2024 | 
eprints.gla.ac.uk | John G.F |van Veldhuisen
Gustafsson, F. et al. (2024) 2-year outcomes of an atrial shunt device in HFpEF/HFmrEF: results from REDUCE LAP-HF II. JACC: Heart Failure, (doi: 10.1016/j.jchf.2024.04.011) (In Press)Full text not currently available from Enlighten.
-
Jun 10, 2024 | 
eprints.gla.ac.uk | van Veldhuisen |John J.V
Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064) Full text not currently available from Enlighten. AbstractBackgroundKidney dysfunction often leads to reluctance to start or continue life-saving heart failure (HF) therapy.
-
Jan 8, 2024 | 
karger.com | van Veldhuisen
Background: Debate exists regarding the optimal treatment for painful chronic pancreatitis (CP). Objectives: This meta-analysis aims to determine the outcomes of surgical intervention as compared to endoscopy in patients with painful CP. Methods: A systematic review and meta-analysis including studies from PubMed, Embase, Web of Science and Cochrane databases (1995 onwards) was done by two independent reviewers using PRISMA guidelines. Primary outcome was pain relief.
-
Sep 3, 2023 | 
eprints.gla.ac.uk | van Veldhuisen |John J.V
Matsumoto, S., Kondo, T., Jhund, P. S. , Campbell, R. T., Swedberg, K., van Veldhuisen, D. J., Pocock, S. J., Pitt, B., Zannad, F. and McMurray, J. J.V. (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608) Full text not currently available from Enlighten.
-
Aug 26, 2023 | 
academic.oup.com | Baylor Scott |Muhammad Shahzeb |van Veldhuisen |CSL Vifor
See the editorial comment for this article ‘Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes’, by H. Abu-Own et al., https://doi.org/10.1093/eurheartj/ehad746.
-
Jun 27, 2023 | 
eprints.gla.ac.uk | João Pedro Nascimento |John J.V |van Veldhuisen
Monzo, L., Girerd, N., Duarte, K., Ferreira, J. P., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Pocock, S. J., Pitt, B. and Zannad, F. (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial.
